CoChat
Sign Up
Cited by 41MicroRNA in disease regulationDementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Circulating Inflamma-miRs as Potential Biomarkers of Cognitive Impairment in Patients Affected by Alzheimer’s Disease

Open access
Giuliani, Angelica, Gaetani, Simona, Sorgentoni, Giulia, Agarbati, Silvia, Laggetta, Maristella, Matacchione, Giulia, Gobbi, Mirko, Rossi, Tommaso +9 more·2021·Frontiers in Aging Neuroscience
DOI 10.3389/fnagi.2021.647015PMC PMC7990771
Open this paper in CoChat — free accountOpen PDF

Abstract

Alzheimer’s disease (AD), the most prevalent neurodegenerative disease in the growing population of elderly people, is still lacking minimally-invasive circulating biomarkers that could facilitate the diagnosis and the monitoring of disease progression. MicroRNAs (miRNAs) are emerging as tissue-specific and/or circulating biomarkers of several age-related diseases, but evidence on AD is still not conclusive. Since a systemic pro-inflammatory status was associated with an increased risk of AD development and progression, we focused our investigation on a subset of miRNAs modulating the inflammatory process, namely inflamma-miRNAs. The expression of inflamma-miR-17-5p, -21-5p, -126-3p, and -146a-5p was analyzed in plasma samples from 116 patients with AD compared with 41 age-matched healthy control (HC) subjects. MiR-17-5p, miR-21-5p, and miR-126-3p plasma levels were significantly increased in AD patients compared to HC. Importantly, a strong inverse relationship was observed between miR-21-5p and miR-126-3p, and the cognitive impairment, assessed by Mini-Mental State Examination (MMSE). Notably, miR-126-3p was able to discriminate between mild and severe cognitive impairment. Overall, our results reinforce the hypothesis that circulating inflamma-miRNAs could be assessed as minimally invasive tools associated with the development and progression of cognitive impairment in AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnagi.2021.647015

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • miR-21 was suggested to have both harmful and beneficial effects.

    “Despite its nonspecificity [33], miR-21 is considered a versatile regulator in the progression of CNS disorders [34] and was suggested to have both harmful and beneficial effects [35,36,37].”

    From Emerging Role of miR-21-5p in Neuron–Glia Dysregulation and Exosome Transfer Using Multiple Models of Alzheimer’s Disease (2022) · cites this paper as [37]

    The Discussion describes evidence for a neuroprotective role for miR-21 in the CNS, supporting the beneficial-effects portion. It says miR-21’s role in neuroinflammation remains unclear, but does not suggest that miR-21 has harmful effects; its conflicting reports concern circulating levels in Alzheimer’s patients, not harmful versus beneficial effects. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 53

  1. Arce Rentería M. Gillett S. R. McClure L. A. Wadley V. G. Glasser S. P. Howard V. J.. (2020). C-reactive protein and risk of cognitive decline: the REGARDS study. PLoS One 15: e0244612. 10.1371/journal.pone.0244612 33382815 PMC7774911 · DOI
  2. Bicker F. Vasic V. Horta G. Ortega F. Nolte H. Kavyanifar A.. (2017). Neurovascular EGFL7 regulates adult neurogenesis in the subventricular zone and thereby affects olfactory perception. Nat. Commun. 8: 15922. 10.1038/ncomms15922 28656980 PMC5493759 · DOI
  3. Blandford S. N. Galloway D. A. Moore C. S. (2018). The roles of extracellular vesicle microRNAs in the central nervous system. Glia 66, 2267– 2278. 10.1002/glia.23445 29726599 · DOI
  4. Blasko I. Marx F. Steiner E. Hartmann T. Grubeck-Loebenstein B. (1999). TNFα plus IFNγ induce the production of Alzheimer β-amyloid peptides and decrease the secretion of APPs. FASEB J. 13, 63– 68. 10.1096/fasebj.13.1.63 9872930 · DOI
  5. Burgos K. Malenica I. Metpally R. Courtright A. Rakela B. Beach T.. (2014). Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer’s and Parkinson’s diseases correlate with disease status and features of pathology. PLoS One 9: e94839. 10.1371/journal.pone.0094839 24797360 PMC4010405 · DOI · Paper page
  6. Clement C. Hill J. M. Dua P. Culicchia F. Lukiw W. J. (2016). Analysis of RNA from Alzheimer’s disease post-mortem brain tissues. Mol. Neurobiol. 53, 1322– 1328. 10.1007/s12035-015-9105-6 25631714 PMC5450164 · DOI
  7. Delay C. Calon F. Mathews P. Hébert S. S. (2011). Alzheimer-specific variants in the 3’UTR of Amyloid precursor protein affect microRNA function. Mol. Neurodegener. 6: 70. 10.1186/1750-1326-6-70 21982160 PMC3195754 · DOI
  8. Franceschi C. Bonafè M. Valensin S. Olivieri F. De Luca M. Ottaviani E.. (2000). Inflamm-aging. An evolutionary perspective on immunosenescence. Ann. N Y Acad. Sci. 908, 244– 254. 10.1111/j.1749-6632.2000.tb06651.x 10911963 · DOI · Paper page
  9. Gámez-Valero A. Campdelacreu J. Vilas D. Ispierto L. Reñé R. Álvarez R.. (2019). Exploratory study on microRNA profiles from plasma-derived extracellular vesicles in Alzheimer’s disease and dementia with Lewy bodies. Transl. Neurodegener. 8: 31. 10.1186/s40035-019-0169-5 31592314 PMC6775659 · DOI
  10. Ge X.-T. Lei P. Wang H.-C. Zhang A.-L. Han Z.-L. Chen X.. (2014). miR-21 improves the neurological outcome after traumatic brain injury in rats. Sci. Rep. 4: 6718. 10.1038/srep06718 25342226 PMC4208064 · DOI · Paper page
  11. Harris T. A. Yamakuchi M. Ferlito M. Mendell J. T. Lowenstein C. J. (2008). MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc. Natl. Acad. Sci. U S A 105, 1516– 1521. 10.1073/pnas.0707493105 18227515 PMC2234176 · DOI
  12. Henriques A. D. Machado-Silva W. Leite R. E. P. Suemoto C. K. Leite K. R. M. Srougi M.. (2020). Genome-wide profiling and predicted significance of post-mortem brain microRNA in Alzheimer’s disease. Mech. Ageing Dev. 191: 111352. 10.1016/j.mad.2020.111352 32920076 · DOI
  13. Hernandez-Segura A. Nehme J. Demaria M. (2018). Hallmarks of cellular senescence. Trends Cell Biol. 28, 436– 453. 10.1016/j.tcb.2018.02.001 29477613 · DOI · Paper page
  14. Hwang D. W. Choi Y. Kim D. Park H. Y. Kim K. W. Kim M. Y.. (2019). Graphene oxide-quenching-based fluorescence in situ hybridization (G-FISH) to detect RNA in tissue: simple and fast tissue RNA diagnostics. Nanomedicine 16, 162– 172. 10.1016/j.nano.2018.12.004 30594658 · DOI
  15. Jones L. Holmans P. A. Hamshere M. L. Harold D. Moskvina V. Ivanov D.. (2010). Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer’s disease. PLoS One 5: e13950. 10.1371/journal.pone.0013950 21085570 PMC2981526 · DOI · Paper page
  16. Jones S. V. Kounatidis I. (2017). Nuclear factor-kappa B and Alzheimer’s disease, unifying genetic and environmental risk factors from cell to humans. Front. Immunol. 8: 1805. 10.3389/fimmu.2017.01805 29312321 PMC5732234 · DOI
  17. Jonsson T. Stefansson H. Steinberg S. Jonsdottir I. Jonsson P. V. Snaedal J.. (2013). Variant of TREM2 associated with the risk of Alzheimer’s disease. N. Engl. J. Med. 368, 107– 116. 10.1056/NEJMoa1211103 23150908 PMC3677583 · DOI · Paper page
  18. Kim W. Noh H. Lee Y. Jeon J. Shanmugavadivu A. McPhie D. L.. (2016). MiR-126 regulates growth factor activities and vulnerability to toxic insult in neurons. Mol. Neurobiol. 53, 95– 108. 10.1007/s12035-014-8989-x 25407931 PMC4437970 · DOI
  19. Ksiazek-Winiarek D. J. Kacperska M. J. Glabinski A. (2013). MicroRNAs as novel regulators of neuroinflammation. Mediators Inflamm. 2013: 172351. 10.1155/2013/172351 23983402 PMC3745967 · DOI
  20. Kumar S. Reddy P. H. (2021). Elevated levels of MicroRNA-455–3p in the cerebrospinal fluid of Alzheimer’s patients: a potential biomarker for Alzheimer’s disease. Biochim. Biophys. Acta 1867: 166052. 10.1016/j.bbadis.2020.166052 33412267 PMC7867567 · DOI
  21. Kumar S. Vijayan M. Reddy P. H. (2017). MicroRNA-455–3p as a potential peripheral biomarker for Alzheimer’s disease. Hum. Mol. Genet. 26, 3808– 3822. 10.1093/hmg/ddx267 28934394 PMC6075184 · DOI · Paper page
  22. Lambert J. C. Heath S. Even G. Campion D. Sleegers K. Hiltunen M.. (2009). Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat. Genet. 41, 1094– 1099. 10.1038/ng.439 19734903 · DOI · Paper page
  23. Lane C. A. Hardy J. Schott J. M. (2018). Alzheimer’s disease. Eur. J. Neurol. 25, 59– 70. 10.1111/ene.13439 28872215 · DOI · Paper page
  24. Leidinger P. Backes C. Deutscher S. Schmitt K. Mueller S. C. Frese K.. (2013). A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol. 14: R78. 10.1186/gb-2013-14-7-r78 23895045 PMC4053778 · DOI
  25. Leng F. Edison P. (2020). Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat. Rev. Neurol. [Epub ahead of print]. 10.1038/s41582-020-00435-y 33318676 · DOI · Paper page
  26. Lescai F. Chiamenti A. M. Codemo A. Pirazzini C. D’Agostino G. Ruaro C.. (2011). An APOE haplotype associated with decreased epsilon4 expression increases the risk of late onset alzheimer’s disease. J. Alzheimers Dis. 24, 235– 245. 10.3233/JAD-2011-101764 21263195 · DOI
  27. Maffioletti E. Milanesi E. Ansari A. Zanetti O. Galluzzi S. Geroldi C.. (2019). miR-146a plasma levels are not altered in Alzheimer’s disease but correlate with age and illness severity. Front. Aging Neurosci. 11: 366. 10.3389/fnagi.2019.00366 32009940 PMC6978630 · DOI
  28. Marchegiani F. Matacchione G. Ramini D. Marcheselli F. Recchioni R. Casoli T.. (2019). Diagnostic performance of new and classic CSF biomarkers in age-related dementias. Aging 11, 2420– 2429. 10.18632/aging.101925 31029057 PMC6520009 · DOI
  29. McKhann G. Drachman D. Folstein M. Katzman R. Price D. Stadlan E. M. (1984). Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology 34, 939– 944. 10.1212/wnl.34.7.939 6610841 · DOI · Paper page
  30. Mengel-From J. Ronne M. E. Carlsen A. L. Skogstrand K. Larsen L. A. Tan Q.. (2018). Circulating, cell-free micro-RNA profiles reflect discordant development of dementia in monozygotic twins. J. Alzheimers Dis. 63, 591– 601. 10.3233/JAD-171163 29660943 PMC6127603 · DOI
  31. Mensà E. Giuliani A. Matacchione G. Gurău F. Bonfigli A. R. Romagnoli F.. (2019). Circulating miR-146a in healthy aging and type 2 diabetes: Age- and gender-specific trajectories. Mech. Ageing Dev. 180, 1– 10. 10.1016/j.mad.2019.03.001 30880174 · DOI
  32. Nikolic I. Plate K. H. Schmidt M. H. H. (2010). EGFL7 meets miRNA-126: an angiogenesis alliance. J. Angiogenes Res. 2: 9. 10.1186/2040-2384-2-9 20529320 PMC2901201 · DOI
  33. Olivieri F. Capri M. Bonafe M. Morsiani C. Jung H. J. Spazzafumo L.. (2017). Circulating miRNAs and miRNA shuttles as biomarkers: perspective trajectories of healthy and unhealthy aging. Mech. Ageing Dev. 165, 162– 170. 10.1016/j.mad.2016.12.004 27986629 PMC5481482 · DOI
  34. Olivieri F. Lorenzi M. Antonicelli R. Testa R. Sirolla C. Cardelli M.. (2009). Leukocyte telomere shortening in elderly Type2DM patients with previous myocardial infarction. Atherosclerosis 206, 588– 593. 10.1016/j.atherosclerosis.2009.03.034 19464008 · DOI
  35. Olivieri F. Rippo M. R. Monsurrò V. Salvioli S. Capri M. Procopio A. D.. (2013a). MicroRNAs linking inflamm-aging, cellular senescence and cancer. Ageing Res. Rev. 12, 1056– 1068. 10.1016/j.arr.2013.05.001 23688930 · DOI
  36. Olivieri F. Rippo M. R. Procopio A. D. Fazioli F. (2013b). Circulating inflamma-miRs in aging and age-related diseases. Front. Genet. 4: 121. 10.3389/fgene.2013.00121 23805154 PMC3693036 · DOI
  37. Olivieri F. Spazzafumo L. Santini G. Lazzarini R. Albertini M. C. Rippo M. R.. (2012). Age-related differences in the expression of circulating microRNAs: miR-21 as a new circulating marker of inflammaging. Mech. Ageing Dev. 133, 675– 685. 10.1016/j.mad.2012.09.004 23041385 · DOI · Paper page
  38. Riphagen J. M. Ramakers I. Freeze W. M. Pagen L. H. G. Hanseeuw B. J. Verbeek M. M.. (2020). Linking APOE-epsilon4, blood-brain barrier dysfunction and inflammation to Alzheimer’s pathology. Neurobiol. Aging 85, 96– 103. 10.1016/j.neurobiolaging.2019.09.020 31733942 · DOI
  39. Sabbatinelli J. Ramini D. Giuliani A. Recchioni R. Spazzafumo L. Olivieri F. (2021). Connecting vascular aging and frailty in Alzheimer’s disease. Mech. Ageing Dev. 195: 111444. 10.1016/j.mad.2021.111444 33539904 · DOI
  40. Saeedi S. Israel S. Nagy C. Turecki G. (2019). The emerging role of exosomes in mental disorders. Transl. Psychiatry 9: 122. 10.1038/s41398-019-0459-9 30923321 PMC6438960 · DOI
  41. Shi Y. Zhang X. Tang X. Wang P. Wang H. Wang Y. (2012). MiR-21 is continually elevated long-term in the brain after exposure to ionizing radiation. Radiat. Res. 177, 124– 128. 10.1667/rr2764.1 22034847 · DOI
  42. Slota J. A. Booth S. A. (2019). MicroRNAs in neuroinflammation: implications in disease pathogenesis, biomarker discovery and therapeutic applications. Noncoding RNA 5: 35. 10.3390/ncrna5020035 31022830 PMC6632112 · DOI
  43. Sonntag K. C. Woo T.-U. W. Krichevsky A. M. (2012). Converging miRNA functions in diverse brain disorders: a case for miR-124 and miR-126. Exp. Neurol. 235, 427– 435. 10.1016/j.expneurol.2011.11.035 22178324 PMC3335933 · DOI
  44. Sutinen E. M. Pirttilä T. Anderson G. Salminen A. Ojala J. O. (2012). Pro-inflammatory interleukin-18 increases Alzheimer’s disease-associated amyloid-β production in human neuron-like cells. J. Neuroinflammation 9: 199. 10.1186/1742-2094-9-199 22898493 PMC3458954 · DOI
  45. Van Cauwenberghe C. Van Broeckhoven C. Sleegers K. (2016). The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet. Med. 18, 421– 430. 10.1038/gim.2015.117 26312828 PMC4857183 · DOI · Paper page
  46. Wade S. M. McGarry T. Wade S. C. Fearon U. Veale D. J. (2020). Serum MicroRNA signature as a diagnostic and therapeutic marker in patients with psoriatic arthritis. J. Rheumatol. 47, 1760– 1767. 10.3899/jrheum.190602 32115427 · DOI
  47. Wingo T. S. Yang J. Fan W. Min Canon S. Gerasimov E. S. Lori A.. (2020). Brain microRNAs associated with late-life depressive symptoms are also associated with cognitive trajectory and dementia. NPJ Genom. Med. 5: 6. 10.1038/s41525-019-0113-8 32047652 PMC7004995 · DOI
  48. Xi T. Jin F. Zhu Y. Wang J. Tang L. Wang Y.. (2017). MicroRNA-126–3p attenuates blood-brain barrier disruption, cerebral edema and neuronal injury following intracerebral hemorrhage by regulating PIK3R2 and Akt. Biochem. Biophys. Res. Commun. 494, 144– 151. 10.1016/j.bbrc.2017.10.064 29042193 · DOI
  49. Xia X. Wang Y. Huang Y. Zhang H. Lu H. Zheng J. C. (2019). Exosomal miRNAs in central nervous system diseases: biomarkers, pathological mediators, protective factors and therapeutic agents. Prog. Neurobiol. 183: 101694. 10.1016/j.pneurobio.2019.101694 31542363 PMC7323939 · DOI
  50. Youden W. J. (1950). Index for rating diagnostic tests. Cancer 3, 32– 35. 10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106<3.0.co;2-3 15405679 · DOI
  51. Zhang L. Dong L.-Y. Li Y.-J. Hong Z. Wei W.-S. (2012). miR-21 represses FasL in microglia and protects against microglia-mediated neuronal cell death following hypoxia/ischemia. Glia 60, 1888– 1895. 10.1002/glia.22404 22907769 · DOI · Paper page
  52. Zhao Y. Jaber V. Alexandrov P. N. Vergallo A. Lista S. Hampel H.. (2020). microRNA-based biomarkers in Alzheimer’s disease (AD). Front. Neurosci. 14: 585432. 10.3389/fnins.2020.585432 33192270 PMC7664832 · DOI
  53. Zhong L. Simard M. J. Huot J. (2018). Endothelial microRNAs regulating the NF-κB pathway and cell adhesion molecules during inflammation. FASEB J. 32, 4070– 4084. 10.1096/fj.201701536R 29565737 · DOI

Cited by

Sorted by citations

Authors
Giuliani, A., Gaetani, S., Sorgentoni, G., Agarbati, S., Laggetta, M., Matacchione, G., Gobbi, M., Rossi, T., Galeazzi, R., Piccinini, G., Pelliccioni, G., Bonfigli, A. R., Procopio, A. D., Albertini, M. C., Sabbatinelli, J., Olivieri, F., & Fazioli, F.
Affiliations
  • Marche Polytechnic University (IT)
  • Istituto Nazionale di Riposo e Cura per Anziani (IT)
  • University of Urbino (IT)
Corresponding author
  • Sabbatinelli, Jacopo
  • Fazioli, Francesca
ORCID
Venue
Frontiers in Aging Neuroscience
Publisher
Frontiers Media SA
Published
2021-03-11
Volume
13
Pages
647015-647015
ISSN
1663-4365 (ISSN-L)
DOI
10.3389/fnagi.2021.647015
PMC
PMC7990771
OpenAlex
W3134354866
Cited by
41
References
5
Citations by year
2026: 7 · 2025: 4 · 2024: 7 · 2023: 4 · 2022: 12 · 2021: 7
FWCI
2.98
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Aging Neuroscience (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion, cc-by)
  • CINECA IRIS Institutional Research information system (University of Urbino) (submittedVersion, cc-by)
Funders
Università  Politecnica delle Marche
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
Alzheimer's disease, microRNA, circulating biomarkers, cognitive impairment, plasma microRNA, miR-17-5p, miR-21-5p, miR-126-3p, miR-146a, neuroinflammation, disease progression, diagnostic biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review